Using genetic variation for establishing causality of cardiovascular risk factors: overcoming confounding and reverse causality by R. A. J. Smit et al.
ICIN
Using genetic variation for establishing causality
of cardiovascular risk factors: overcoming confounding
and reverse causality
R. A. J. Smit & S. Trompet & A. J. M. de Craen &
J. W. Jukema
Published online: 4 March 2014
# The Author(s) 2014. This article is published with open access at Springerlink.com
Abstract Cardiovascular disease (CVD) remains the leading
cause of death in developed countries, despite the decline of
CVDmortality over the last two decades. From observational,
predictive research, efforts have been made to find causal risk
factors for CVD. However, in recent years, some of these
findings have been shown to be mistaken. Possible explana-
tions for the discrepant findings are confounding and reverse
causation. Genetic epidemiology has tried to address these
problems through the use of Mendelian randomisation. In this
paper, we discuss the promise and limitations of using genetic
variation for establishing causality of cardiovascular risk
factors.
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Cardiovascular disease (CVD) remains the leading cause of
death in developed countries. This is unlikely to changewithin
the near future, despite the decline of CVD mortality over the
last two decades [1]. One of the pivotal studies that broadened
our understanding of cardiovascular risk is the Framingham
Heart Study. Since its inception in 1948, this study has iden-
tified various major risk factors contributing to CVD, includ-
ing hypertension and elevated lipid concentrations [2].
Moreover, the Framingham Heart Study has generated one
of the first multivariate cardiovascular risk prediction scores
[3]. From observational, predictive research, efforts have been
made to also assess likely causal relationships. However, in
recent years, some of these findings have been called into
question and ultimately proven wrong.
One of the most profound examples of such high-profile
misidentification is the risk-lowering effect of hormone-
replacement therapy on coronary heart disease found in ob-
servational studies, leading to widespread prescription of hor-
mones for post-menopausal women. Subsequent randomised
controlled trials (RCTs) showed that hormone therapy not
only fails to lower cardiovascular risk, but may also even
increase mortality risk and lead to other adverse clinical out-
comes [4, 5]. Similar over-turnings were seen for vitamins E
and C after RCTs disproved any cardioprotective effects [6]. It
has been argued that the most likely explanations for these
discrepancies have been confounding by environmental and
behavioural factors, baseline health status, and prescription
policies, combined with reverse causation and selection bias
[7]. This shows that observational studies have certain weak-
nesses. Similar limitations might be present for RCTs, which
are still viewed as the gold standard in estimation of causality.
Firstly, it is sometimes unethical or impractical to allocate
participants to exposures of interest (e.g. elevated blood pres-
sure or physical inactivity). Additionally, participants are often
relatively healthy with few co-morbidities which limits the
applicability of the study findings to the general population,
worsened by the possibility of consent bias. Lastly, trials may
need significant follow-up time to produce meaningful results,
which means RCTs are relatively resource-intensive and
expensive.
Genetic epidemiology has tried to address these concerns
through the use of Mendelian randomisation studies. While
this term was introduced by Gray and Wheatley in 1991 [8],
the underlying principles have long been recognised and
applied in the field of econometrics, taking the form of
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instrumental variable analysis. An instrumental variable (or
instrument) is a variable associated with the exposure, but not
with the outcome of interest except through its association
with the exposure [9]. The application of Mendelian
randomisation in biomedical research, credited to Katan
[10], is based on the concept that inheritance of germ line
genetic variants is subject to the random allocation of alleles at
conception, more commonly known as Mendel’s second law
or the law of independent assortment [11]. As the associations
between genotype and clinical outcome are generally unrelat-
ed to environmental or behavioural exposures, the use of
single nucleotide polymorphisms (SNPs) known to be associ-
ated with modifiable risk factors makes it possible to avoid
possible confounding or reverse causality (Fig. 1). In other
words, causality of these risk factors can accurately be esti-
mated using observational data in a research design resem-
bling an RCT (Fig. 2) [12].
A clear example where Mendelian randomisation was suc-
cessfully used to prove the causality of a possible risk factor is
the secretory phospholipase A2 (sPLA2) story. Higher circu-
lating levels of sPLA2-IIA mass or sPLA2 enzyme activity
have been associated with increased risk of cardiovascular
events in observational studies [13]. However, a recent RCT
with varespladib, a sPLA2 inhibitor, was stopped because of
lack of efficacy. Subjects randomised to varespladib had an
increased risk for cardiovascular events compared with sub-
jects receiving placebo [14]. A Mendelian randomisation
study was conducted to investigate the causality of sPLA2 in
cardiovascular disease. The polymorphism rs11573156,
which was associated with significantly lower sPLA2 levels,
was not associated with coronary events (OR 1.02 (95 % CI
0.98–1.06)). The conclusion from this Mendelian
randomisation study was that sPLA2-lowering therapy would
not be a useful therapeutic tool to prevent cardiovascular
disease [15].
To test whether elevated levels of C-reactive protein (CRP)
are causally associated with ischaemic vascular disease,
Zacho et al. conducted genotyping for four CRP polymor-
phisms. They found that the risk of ischaemic heart disease
and ischaemic cerebrovascular disease was increased by a
factor of 1.6 and 1.2, respectively, in persons who had CRP
levels above 3 mg/l, as compared with persons who had CRP
levels below 1 mg mg/l. Polymorphisms in the CRP gene
were associated with considerable increases in CRP levels and
thus with a theoretically predicted increase in the risk of
ischaemic vascular disease. However, these polymorphisms
were not associated with an increased risk of ischaemic vas-
cular disease, thereby demonstrating that a causal relationship
of CRP levels with adverse cardiovascular outcome is unlike-
ly [16].
Another example of a Mendelian randomisation, originat-
ing from Katan’s original hypothesis, used apolipoprotein E
(ApoE) genotype to infer causality between cholesterol and
cancer [10, 17]. The background for this was the uncertainty
whether the associations found between low plasma choles-
terol levels and increased risk of cancer might actually reflect
a hypocholesterolaemic effect of cancer in preclinical stages
[10]. Trompet et al. reported that subjects within the lowest
third of plasma cholesterol levels had increased risk of cancer
incidence (HR 1.9 (95 % CI 1.34–2.70)) and cancer mortality
(HR 2.03 (95 % CI 1.23–3.34)), when compared with those
within the highest third of plasma cholesterol levels. However,
they also found that carriers of the ApoE2 genotype, who had
9 % lower plasma cholesterol than carriers of the ApoE4
Fig. 1 Causal relationships
which satisfy the core
assumptions of Mendelian
randomisation: (1) genotype is
associated with phenotype, (2)
genotype is independent of
confounding factors, and (3)
genotype is associated with
outcome, but only through
phenotype
Fig. 2 Comparison of randomised controlled trial and Mendelian
randomisation study designs
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genotype, did not have increased risk of cancer incidence (HR
0.86 (95%CI 0.50–1.47)) or cancer mortality (HR 0.70 (95%
CI 0.30–1.60)) compared with ApoE4 carriers. These findings
suggested that low cholesterol levels are not causally related to
increased cancer risk [17].
An important limitation ofMendelian randomisation is that
genetic variants generally explain a modest amount of the
variation in exposure levels, which means large sample sizes
are needed to obtain valid results. It has been suggested that
combining multiple SNPs into an allele score increases power
and facilitates avoidance of weak instrument bias [18, 19].
Genome-wide association studies (GWAS), which scan large
numbers of genetic markers in genomes of different individ-
uals to find genetic variations associated with a particular
disease or trait, have made construction of these genetic risk
scores feasible. Teslovich et al. found 95 loci associated with
plasma lipids in more than 100,000 individuals, explaining
9.6–12.4 % of total variance of lipid levels in the Framingham
Heart Study and corresponding to ∼25–30 % of the genetic
variance for each trait [20]. Other large-scale GWAS have
examined traits of blood pressure [21], body mass index
[22], and CRP [23], providing more insight into the genetics
and biology of these possible risk factors.
Various studies have applied GWAS findings to examine
causality of cardiovascular risk factors. For example, Voight
et al. constructed a genetic risk score comprising 14 SNPs
known to be associated with HDL cholesterol but not with
other lipid traits. While observational epidemiology showed
that an increase of 1 SD in HDL cholesterol was associated
with decreased occurrence of myocardial infarction (OR 0.62
per SD (95 % CI 0.58–0.66)), genetically raised HDL was not
associated with risk of myocardial infarction (OR 0.93 per SD
(95 % CI 0.68–1.26)), thereby challenging the concept that
raising plasma HDL cholesterol leads to reductions in risk of
myocardial infarction. In contrast, the estimate from observa-
tional epidemiology for LDL cholesterol (OR 1.54 per SD
(95 % CI 1.45–1.63)) was concordant with that from geneti-
cally raised LDL (OR 2.13 per SD (95 % CI 1.69–2.69)) [24].
In another recent study, a total of 30 SNPs were combined by
Lieb et al. to evaluate whether hypertension truly acts as a
causative factor for coronary artery disease, finding that those
individuals carryingmost systolic and diastolic blood pressure
raising risk alleles had the highest odds of having coronary
artery disease [25].
Most research has been performed using data from
Caucasian populations only, which illustrates one of the lim-
itations to the application of genetic risk scores in clinical
practice. It is unlikely that Mendelian randomisation findings
will uniformly translate into treatment effects as clinical inter-
ventions may have additional biological and biochemical
pathways through which they affect clinical outcome, though
the findings will generally be informative for the direction of
effect and may further the design of an intervention study. In
general, Mendelian randomisation studies must examine the
possibility of potential confounders to genotype. This includes
confounding through multiple functions of a genotype
(pleiotropy), the non-random association of alleles at two or
more loci (linkage disequilibrium), population stratification,
and canalisation, which describes a foetal developmental
change in response to a potentially harmful genetic variant
[12].
Despite its current challenges, genetic epidemiology has
great potential for extending the knowledge base of cardio-
vascular risk assessment. With increasing sample sizes and
next-generation sequencing, GWAS will be able to detect
increasing numbers of trait- and disease-associated genetic
variants. Recently, the Global Lipids Genetics Consortium
identified 157 loci associated with lipid levels, including 62
loci not previously associated with lipid levels in humans,
thereby extending the findings of Teslovich et al. and opening
up new possibilities for construction of genetic risk scores
[26]. Moreover, in coming years, academic cooperation
through international research consortia (e.g. CHARGE,
GIANT, IDEAL) will present unprecedented possibilities for
translational and (pre)clinical research.
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